Why did my tremor get worse after starting penicillamine — and will it reverse?

If your tremor — or other neurological symptoms — became noticeably worse in the weeks after starting penicillamine, you are almost certainly not imagining it, and the drug very likely played a role. This is one of the most distressing experiences patients with neurological Wilson disease can have: you start what should be a helpful treatment, and you get worse instead of better. It has a name — neurological worsening — and it happens to a meaningful number of patients.

The important things to know up front: it is a recognized complication, not a sign that your Wilson disease is untreatable. For most patients who experience it, neurological status does stabilize, and many improve — sometimes substantially — after a change in treatment. Recovery can take months, and it is rarely immediate, but it is real.¹

Why does penicillamine make some people worse?

The prevailing explanation is something called “copper redistribution.” Penicillamine is a potent copper chelator — it binds copper in tissues and pulls it out into the bloodstream for excretion via the kidneys. When treatment starts, this happens quickly, and more copper becomes transiently available in the circulation.² In patients who already have neurological involvement, this surge of mobilized copper is thought to reach the brain, temporarily worsening the same symptoms the drug is meant to eventually improve.

This mechanism is consistent with what researchers and clinicians have observed: neurological worsening is more likely to occur at higher starting doses, in patients with established neurological disease at baseline, and in the early weeks of treatment before excretion catches up.³ It is less common in patients who present with purely liver disease.

Ranjan and colleagues documented MRI changes alongside oxidative stress markers in patients who worsened neurologically after penicillamine, providing further evidence that the mechanism involves acute copper mobilization affecting brain tissue.⁴

How common is it?

Studies and case series suggest that neurological worsening after starting penicillamine occurs in roughly 10–50% of patients with neurological Wilson disease, depending on how it is defined and measured. A systematic analysis by Mohr and colleagues proposed clearer classifications to distinguish transient worsening from sustained deterioration, and found that outcomes varied considerably depending on what was done next.¹

Kalita and colleagues described a series of patients in whom worsening was severe enough to cause significant functional decline, emphasizing the importance of early recognition and management changes.⁵

Is this definitely the drug, or is it my disease progressing?

This is a real and difficult question. Wilson disease itself can progress before treatment has had time to work. Distinguishing drug-induced worsening from disease progression is challenging, and it is one reason neurological Wilson disease is best managed by teams with experience in this condition.

The clues that point toward penicillamine as the cause include:

• Worsening started within days to weeks of beginning the drug
• The symptom pattern is similar to what was already present, rather than new symptoms in different areas
• You had not yet reached adequate copper excretion levels before the worsening occurred
• Things stabilize when the dose is reduced or the drug is changed

Your specialist may also use serial MRI, repeat copper studies, and neurological scoring scales to track what is happening and make the call.

What happens next — and will I recover?

The most common response, when penicillamine is identified as causing neurological worsening, is to either reduce the dose dramatically or switch to a different agent.⁶ The two main alternatives are:

Trientine: This chelator also removes copper through the urine, but evidence suggests it mobilizes copper more gradually than penicillamine. It has become the preferred agent for initiating treatment in patients with neurological Wilson disease precisely because the risk of worsening appears lower.⁷ Switching from penicillamine to trientine in a patient who has worsened is a reasonable and well-supported approach.

Zinc: In some cases, particularly when worsening has been severe, zinc salts may be started instead of or alongside a lower-dose chelator. Zinc works differently — it blocks copper absorption from the gut rather than mobilizing existing stores — and so does not carry the same redistribution risk. It works more slowly but may allow neurological stability while copper levels gradually normalize.

Kumar and colleagues reviewed management strategies for children and adolescents who worsened on penicillamine and found that switching to trientine or zinc led to neurological stabilization in most cases, with partial or complete recovery occurring over months.⁶

Recovery timelines are frustratingly slow. Neurological Wilson disease responds to treatment at the pace of nerve recovery and copper clearance, not within days. Some patients see meaningful improvement within three to six months of switching therapy; others take considerably longer. A small proportion of patients, particularly those with the most severe initial worsening, do not recover fully to their pre-drug baseline — which is part of why preventing this complication through careful prescribing is so important.¹

What about the evidence for low-dose penicillamine instead of switching?

Some specialists prefer to continue penicillamine but at a much lower initial dose, with very slow escalation, rather than switching drugs entirely. Kundu published longitudinal data on neurological Wilson disease patients treated with low-dose penicillamine and found reasonable outcomes in a subset of patients, suggesting that dose management — not just drug choice — is part of the picture.⁸

This approach is controversial and not universally recommended. The 2022 AASLD guidance leans toward trientine as the preferred first-line agent in neurological presentations specifically because the worsening risk is lower from the start.⁷

What you should do right now

If your tremor or other neurological symptoms have worsened since starting penicillamine:

1. Contact your specialist promptly — do not wait for your next scheduled appointment.
2. Do not stop the drug without guidance — abrupt discontinuation of any copper-lowering therapy can be destabilizing.
3. Ask specifically about switching to trientine, and about what monitoring can be done to track your trajectory.

This is also a situation where a second opinion from a center that sees a high volume of Wilson disease patients is entirely reasonable. The management of neurological worsening is nuanced and benefits from experienced eyes.

See medications-overview for a broader comparison of how penicillamine and trientine differ, and what-to-tell-doctor for how to describe your symptoms clearly at your appointment.

This article is for patient education only. If you are experiencing new or worsening neurological symptoms after starting any Wilson disease medication, contact your medical team. Do not adjust your medication on your own.

References